Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Inclusion Criteria

• •Age greater than or equal to 18 years; no upper age limit.
• •Patients diagnosed with a leukemia or lymphoma as follows:
• •* Chronic or acute leukemia forms of Human T-cell lymphotropic virus type 1 (HTLV-1) associated adult T-cell leukemia;
• •* Peripheral T-cell lymphoma (angioimmunoblastic, hepatosplenic, or not otherwise specified); or,
• •* Cutaneous T-cell lymphoma stage III or IV with circulating monoclonal cells (B1 or B2) and/or erythrodermia (T4)
• •* T-cell prolymphocytic leukemia (T-PLL)
• •NOTE: Diagnosis must be validated by the Pathology Department, National Cancer Institute (NCI).
• •Patients must have measurable or evaluable disease.
• •NOTE: All patients with greater than 10% abnormal cluster of differentiation 4 (CD4+) homogeneous cluster of differentiation 3 (CD3) low strongly cluster of differentiation 25 (CD25+) expressing cells, or greater than 5% Szary cells/T-PLL, among the peripheral blood mononuclear cells (PBMCs) in the peripheral blood will be deemed to have evaluable disease.
• •Abnormal T cells must be cluster of differentiation 52 (CD52+) as assessed by flow cytometry or immunohistochemistry.
• •Patients must have a life expectancy of greater than or equal to 2 months.
• •Patients must have been refractory or relapsed following front line therapy for Adult T-cell Leukemia (ATL); those with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) who have cluster of differentiation 30 (CD30+) disease must have progressed during or after treatment with brentuximab vedotin, or are unable to receive treatment due to allergy or intolerance.
• •Patients must have recovered to less than grade 1 or to baseline from toxicity of prior chemotherapy or biologic therapy and must not have had major surgery, chemotherapy, radiation or biologic therapy within 2 weeks prior to beginning treatment. NOTE: Exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the PI (e.g., alopecia).
• •Carbon monoxide diffusing capacity alveolar volume (DLCO/VA) and forced expiratory volume (FEV) 1.0 \> 50% of predicted on pulmonary function tests.
• •Adequate laboratory parameters, as follows:
• •* Serum creatinine of less than or equal to 1.5 x the upper limit of normal
• •* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x the upper limit of normal
• •Absolute neutrophil count greater than or equal to 1,500/mm\^3 and platelets greater than or equal to 100,000/mm\^3.
• •Eastern Cooperative Oncology Group (ECOG) less than or equal to 1.
• •Patients must be able to understand and sign an Informed Consent Form.
• •All patients must use adequate contraception during participation in this trial and for 4 months following completing therapy.